AI agents are moving from demos into day-to-day clinical operations, but not every workflow is a good fit. This guide explains which clinical trial workflows are realistic for AI agents today, from TMF filing to clinical monitoring, and where people still need to make the call.
Clinical trial workflows that are realistic for AI agents today
These workflows are high-volume, rules-based, and easy to check, so an agent can do the work while a person spot-checks the results.
TMF filing and quality control
TMF filing is probably the best fit for AI agents in clinical operations. An agent can classify incoming documents against the TMF reference model, extract metadata (study, site, document date, version, signatory), file each document to the correct artifact, and check completeness against the expected documents list. It can also catch missing signatures, expired CVs and licenses, and mismatched dates. The common pattern is confidence-scored auto-filing, with low-confidence items routed to a human reviewer.
Site and study start-up documents
Agents can collect and check regulatory packets, Form FDA 1572s, financial disclosures, and training records, track submission status, and draft follow-ups to sites. The checklist is defined, so verification is straightforward.
Document drafting from templates
Site-specific informed consent forms from a master ICF, protocol-derived plans, and monitoring visit letters are all template-driven. The agent drafts; a human approves anything final.
Data query and cleaning triage
Agents can draft data queries, route them to the right site, summarize open queries, and spot patterns, such as one site generating the same error repeatedly.
Study status reporting
Pulling enrollment, deviation, and metrics data from the CTMS, EDC, and eTMF into a status summary is tedious for people and low risk for an agent.
Workflows that are realistic with a human in the loop
Here the agent does the preparation and analysis, and a qualified person makes the decision.
Clinical monitoring
AI agents can take on much of the preparation and analysis side of clinical monitoring:
- Pre-visit review of open queries, outstanding action items, and prior findings
- Risk-based monitoring signal detection, such as unusual data patterns, late data entry and outlier sites
- Drafting monitoring visit reports from monitor notes and system data
- Tracking closure of follow-up items
The on-site work stays with the clinical research associate (CRA): judging source data verification, building rapport with site staff, and assessing whether the site truly understands the protocol. Remote and centralized monitoring is where agents will take on the most.
Protocol deviation management
Agents can detect candidate deviations from EDC and visit data, categorize them, and draft entries. Humans decide whether a deviation matters and what corrective action to take.
Safety case intake
In pharmacovigilance, agents can handle intake, data extraction, MedDRA coding suggestions and duplicate detection. Medical assessment, causality, and expedited reporting decisions require qualified humans.
Site feasibility and selection
Agents can synthesize historical site performance, enrollment data, and investigator history into ranked recommendations for the study team to review.
Medical coding and reconciliation
Agents can suggest codes and reconcile discrepancies between systems, with coder review.
Protocol digitization and study document generation
Protocols are interpreted and recreated repeatedly across documents, workflows, and systems. An agent can turn the protocol into structured, version-controlled data and generate downstream documents from it, with scientists reviewing and approving the output.
An agent can convert protocol content into structured data aligned with a standard such as CDISC's Unified Study Definitions Model (USDM), capturing schedules, endpoints, eligibility criteria, risk domains and operational logic. It can then generate the statistical analysis plan (SAP), data management plan (DMP), clinical monitoring plan (CMP), and study-build activities from that shared foundation. Because every document comes from one source, they stay synchronized when a protocol amendment arrives, and each output can carry source traceability.
PI review of remotely captured data
Principal investigators need to oversee remotely captured participant data, which has traditionally meant checking several reports and systems. An agent can monitor the data continuously and prepare the PI for review and sign-off, while the PI keeps full control.
A review agent can monitor eCOA and other electronically collected participant data and summarize the most recent responses. It should surface the underlying data so the PI can review responses and make updates before signing, with a clear record of what was reviewed and when. Review and sign-off should not block site or participant activity.
How to tell if a clinical trial workflow is ready for an AI agent
A workflow is a good agent candidate when it passes three tests: it is document- and rules-heavy, its output can be verified, and the cost of an error is manageable. We call this the three-question readiness test.
- Is the work document- and rules-heavy? Agents perform best when inputs are documents, emails, or system records, and the standard is written down, such as the TMF reference model or a protocol.
- Can the output be verified? If a person or a downstream check can quickly confirm the result (was the document filed in the right artifact, is the date correct), you can measure accuracy and build validation evidence.
- What does an error cost? A misfiled document is cheap to fix. A wrong causality call on a serious adverse event is not. The higher the cost, the more the agent should assist rather than decide.
Workflows that score well on all three can be run by an agent with human spot-checks. Workflows that fail the third question stay human-led, no matter what the technology can do.
What AI agents should not do in clinical trials
Some work should stay human-led, no matter how capable the technology becomes, because the cost of error is high and accountability cannot be delegated.
- Final medical judgment on adverse events, eligibility edge cases, or benefit-risk.
- Direct patient-facing decisions without clinical oversight.
- Sign-off on data integrity or regulatory attestations.
- Sole accountability for any outcome. Sponsors and principal investigators retain regulatory accountability regardless of the tools they use.
The practical rule is that agents can prepare, flag, and recommend, and qualified people decide.
How to deploy AI agents in a GxP-regulated trial
Using AI agents in clinical trials is workable under existing GxP expectations, provided the agent is controlled, validated, and overseen like any other computerized system. Six practices matter most:
- Audit trails. Every agent action should be attributable, timestamped, and reconstructable, in line with ALCOA+ data integrity principles and 21 CFR Part 11 and EU Annex 11.
- Risk-based validation. Under a computer software assurance (CSA) mindset, document performance evidence in proportion to risk, especially classification and extraction accuracy.
- Confidence thresholds and escalation. Let the agent act on high-confidence items, queue the rest for review, and track the human override rate over time.
- Human accountability. ICH E6(R3) supports risk-proportionate, technology-enabled approaches, but sponsors and investigators retain oversight responsibilities.
- System integration. Much of the value comes from agents working across the EDC, CTMS, eTMF and email, not summarizing in isolation.
- Inspection readiness. Inspectors will ask how you oversee the agent, so define roles, procedures and monitoring from the start.
Where to start: a five-step roadmap for clinical operations teams
Start with workflows that share the same profile: high volume, rules-based, easy to measure, and with a clear human checkpoint. That lets you show return on investment and build validation evidence before moving to higher-judgment work.
- TMF classification, QC and completeness checking.
- Start-up document collection and verification.
- Monitoring report drafting and pre-visit preparation.
- Query and deviation triage.
- Cross-system study status reporting.
Conclusion: start with the paperwork, keep humans on the judgment
AI agents are already realistic for the document-heavy, rules-based work that slows clinical trials down, led by TMF filing and QC, start-up documents, query triage and status reporting. Monitoring, deviations and safety intake benefit from agents too, as long as qualified people make the calls. The teams that succeed treat agents like any other regulated system: validated, auditable and overseen.
